(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- From Dread to Certainty: Individual Accounts of Strengthening
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- The Best Games On the planet
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- Sustaining Public activity and Connections: Key Methodologies
